Kane Biotech Appoints Dr. Sarah Prichard, M.D. to the Board of Directors
02 Abril 2014 - 9:12AM
Marketwired
Kane Biotech Appoints Dr. Sarah Prichard, M.D. to the Board of
Directors
WINNIPEG, MANITOBA--(Marketwired - Apr 2, 2014) - Kane Biotech
Inc. (TSX-VENTURE:KNE), a biotechnology company developing and
commercializing products that prevent and remove microbial biofilms
announces today the appointment of Dr. Sarah Prichard, M.D. FRCP(C)
to its board of directors.
Dr. Prichard has served as global Vice President of R&D,
Renal Medical and Therapeutic Area Leader, Baxter Healthcare from
2005-2014. Prior to this role, she was on faculty at McGill
University from 1979-2005.
Dr. Prichard received her MD from Queens University and trained
in Internal Medicine and Nephrology at McGill University. While at
McGill, she served as Associate Dean of Medicine, Chief of Service
for the Department of Medicine, Senior Physician and Director of
Peritoneal Dialysis at the Royal Victoria Hospital. She was the
President of the Canadian Society of Nephrology (1997-2000) and
President of the International Society of Peritoneal Dialysis
(2001-2004). During her academic career, she published extensively
in the area of dialysis, lectured around the globe and received the
Osler Award for teaching.
Sarah has also played leadership roles as a member of the Board
of Queens University, Chair of the Board of St. Mary's Hospital
Center in Montreal and a member of the Governing Council of CIHR
(Canadian Institute of Health Research).
Her current interests are in product innovation, market access
and global health policies.
"On behalf of the board of directors and the management and
staff of Kane Biotech, I am pleased to welcome Sarah as a director.
We look forward to the insight, guidance and expertise that she
will bring to the Company," stated Gord Froehlich, President and
CEO of Kane Biotech Inc.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the
development and commercialization of products that prevent and
remove biofilms. Biofilms develop when bacteria and other
microorganisms form a protective matrix that acts as a shield
against attack. When in a biofilm, bacteria become highly resistant
to antibiotics, biocides, disinfectants, high temperatures and host
immune responses. This resiliency contributes to human health
problems such as recurrent urinary tract infections, medical device
associated infections and tooth decay.
Kane Biotech uses patent protected technologies based on
molecular mechanisms of biofilm formation/dispersal and methods for
finding compounds that inhibit or disrupt biofilms. The Company has
evidence that these technologies have potential to significantly
improve the ability to prevent and/or destroy biofilms in several
medical and industrial applications.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release
constitute forward-looking information within the meaning of
applicable Canadian provincial securities legislation
(collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals,
targets, strategies, intentions, plans, beliefs, estimates and
outlook, including, without limitation, our anticipated future
operating results, and can, in some cases, be identified by the use
of words such as "believe," "anticipate," "expect," "intend,"
"plan," "will," "may" and other similar expressions. In addition,
any statements that refer to expectations, projections or other
characterizations of future events or circumstances are
forward-looking statements.
These statements reflect management's current beliefs and
are based on information currently available to management. Certain
material factors or assumptions are applied in making
forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ
materially from these expectations include, among other things:
Kane's early stage of development, lack of product revenues and
history of operating losses, uncertainties related to clinical
trials and product development, rapid technological change,
uncertainties related to forecasts, competition, potential product
liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters,
management of growth, partnerships for development and
commercialization of technology, effects of insurers' willingness
to pay for products, system failures, dependence on key personnel,
foreign currency risk, risks related to regulatory matters and
risks related to intellectual property and other risks detailed
from time to time in Kane's filings with Canadian securities
regulatory authorities, as well as Kane's ability to anticipate and
manage the risks associated with the foregoing. Kane cautions that
the foregoing list of important factors that may affect future
results is not exhaustive. When relying on Kane's forward-looking
statements to make decisions with respect to Kane, investors and
others should carefully consider the foregoing factors and other
uncertainties and potential events.
These risks and uncertainties should be considered carefully
and prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management
believes to be reasonable assumptions, Kane cannot provide
assurance that actual results will be consistent with these
forward-looking statements. Kane undertakes no obligation to update
or revise any forward-looking statement.
StrixNB™, DispersinB® and Aledex® are registered trademarks
of Kane Biotech Inc. All Rights Reserved 2014.
Kane Biotech Inc.Gord FroehlichPresident &
CEO204-477-7592204-474-7552ir@kanebiotech.comwww.kanebiotech.com
Kane Biotech (TSXV:KNE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Kane Biotech (TSXV:KNE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024